Group 1 - The company has initiated two new drug research projects in the first half of 2025, focusing on broad-spectrum anti-snake venom antibodies and recombinant snake venom coagulase, currently in the laboratory research phase [1] - The company's export of anti-snake venom serum raw liquid to South Korea is noted, with both the export business amount and its proportion in operating revenue being very small [1] - Specific data regarding overseas operating revenue can be referenced in the company's annual reports [1]